Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo ...

Eli Lilly’s weight loss drug, Zepbound, has been shown to lead to more significant weight loss than Novo Nordisk’s Wegovy, ...

Shares of Eli Lilly climbed early Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss ...

One of Eli Lilly's potential competitors in the weight loss market just reported unimpressive trial results. The company ...

Those treated with tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist, lost on ...

Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from ...

Key Takeaways Patients taking Eli Lilly's Zepbound lost more weight on average than those on Novo Nordisk's Wegovy in a new ...

The pharmaceutical giant presented mid-stage trial data on the pill, muvalaplin, at the American Heart Association Scientific ...

picture alliance / Contributor / Getty Images Eli Lilly and Novo Nordisk shares rose Tuesday after the Biden administration proposed expanding coverage of the companies' weight-loss drugs in ...

GLP-1 medications are breakthroughs for weight loss, diabetes, and more. Pharma companies are clamoring to produce pills or ...

Eli Lilly and Novo Nordisk shares rose Tuesday after the Biden administration proposed expanding coverage of the companies' weight-loss drugs in government-backed healthcare plans. The proposal ...

We recently compiled a list of the Billionaire Ken Fisher’s Top 15 Stock Picks Heading Into 2025. In this article, we are ...